{"id":742222,"date":"2012-04-27T17:05:00","date_gmt":"2012-04-27T17:05:00","guid":{"rendered":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-wins-u-s-zetia-ezetimibe-vytorin-ezetimibe-simvastatin-patent-infringement-lawsuit\/"},"modified":"2023-03-22T00:04:24","modified_gmt":"2023-03-22T04:04:24","slug":"merck-wins-u-s-zetia-ezetimibe-vytorin-ezetimibe-simvastatin-patent-infringement-lawsuit","status":"publish","type":"news_item","link":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-wins-u-s-zetia-ezetimibe-vytorin-ezetimibe-simvastatin-patent-infringement-lawsuit\/","title":{"rendered":"Merck Wins U.S. ZETIA\u00ae (ezetimibe)\/ VYTORIN\u00ae (ezetimibe\/simvastatin) Patent Infringement Lawsuit"},"content":{"rendered":"<p>WHITEHOUSE STATION, N.J.&#8211;(BUSINESS WIRE)&#8211;Merck (NYSE: MRK), known as MSD outside the United States and Canada,        announced today that the U.S. District Court for the District of New        Jersey has ruled in Merck&#8217;s favor in two jointly related patent        infringement suits against Mylan Pharmaceuticals Inc.     <\/p>\n<p>       &#8220;The court appropriately ruled that the patent for ZETIA and VYTORIN in        the U.S. is valid and enforceable,&#8221; said Bruce N. Kuhlik, executive vice        president and general counsel of Merck. The patent at issue in this        trial is RE 42,461 which covers ezetimibe, an active ingredient in both        ZETIA and VYTORIN and expires April 2017.     <\/p>\n<p>       In its decision, the court upheld Merck&#8217;s patent on ZETIA and VYTORIN        and ruled that the patent was valid and enforceable. Mylan had admitted        that its product would infringe the patent. The court also issued an        injunction blocking the approval of Mylan&#8217;s generic versions until the        expiration of the patent.     <\/p>\n<p>       Mylan had been seeking U.S. Food and Drug Administration (FDA) approval        to sell generic versions of ZETIA and VYTORIN. In December 2009, Merck        filed the lawsuit against Mylan in respect of Mylan\u2019s application to the        FDA seeking pre-patent expiry approval to sell a generic version of        VYTORIN and in June 2010, Merck filed a separate lawsuit against Mylan        in respect of Mylan&#8217;s application seeking pre-patent approval to sell a        generic version of ZETIA.     <\/p>\n<p>       Judge Jose Linares presided over the trial. Merck was represented by        Sidley Austin LLP, Lowenstein Sandler PC and Robinson, Wettre &#038; Miller        LLC.     <\/p>\n<p>       <b>About Merck<\/b>     <\/p>\n<p>       Today&#8217;s Merck is a global healthcare leader working to help the world be        well. Merck is known as MSD outside the United States and Canada.        Through our prescription medicines, vaccines, biologic therapies, and        consumer care and animal health products, we work with customers and        operate in more than 140 countries to deliver innovative health        solutions. We also demonstrate our commitment to increasing access to        healthcare through far-reaching policies, programs and partnerships. For        more information, visit <a target=\"_blank\" href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&#038;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated&#038;esheet=50257102&#038;lan=en-US&#038;anchor=vip2-msd.com\/merckcom-migrated&#038;index=1&#038;md5=dcfdc3b754c42e9a1707a0f251192cdb\" rel=\"noopener\">vip2-msd.com\/merckcom-migrated<\/a>        and connect with us on Twitter, Facebook and YouTube.     <\/p>\n<p>       <b>Forward-Looking Statement<\/b>     <\/p>\n<p>       This news release includes \u201cforward-looking statements\u201d within the        meaning of the safe harbor provisions of the United States Private        Securities Litigation Reform Act of 1995. Such statements may include,        but are not limited to, statements about the benefits of the merger        between Merck and Schering-Plough, including future financial and        operating results, the combined company\u2019s plans, objectives,        expectations and intentions and other statements that are not historical        facts. Such statements are based upon the current beliefs and        expectations of Merck\u2019s management and are subject to significant risks        and uncertainties. Actual results may differ from those set forth in the        forward-looking statements.     <\/p>\n<p>       The following factors, among others, could cause actual results to        differ from those set forth in the forward-looking statements: the        possibility that all of the expected synergies from the merger of Merck        and Schering-Plough will not be realized, or will not be realized within        the expected time period; the impact of pharmaceutical industry        regulation and health care legislation in the United States and        internationally; Merck\u2019s ability to accurately predict future market        conditions; dependence on the effectiveness of Merck\u2019s patents and other        protections for innovative products; and the exposure to litigation        and\/or regulatory actions.     <\/p>\n<p>       Merck undertakes no obligation to publicly update any forward-looking        statement, whether as a result of new information, future events or        otherwise. Additional factors that could cause results to differ        materially from those described in the forward-looking statements can be        found in Merck\u2019s 2011 Annual Report on Form 10-K and the company\u2019s other        filings with the Securities and Exchange Commission (SEC) available at        the SEC\u2019s Internet site (<a target=\"_blank\" href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&#038;url=http%3A%2F%2Fwww.sec.gov&#038;esheet=50257102&#038;lan=en-US&#038;anchor=www.sec.gov&#038;index=2&#038;md5=47e0328d323630c19ba53e5c5639f70a\" rel=\"noopener\">www.sec.gov<\/a>).     <\/p>\n<p><p>       Merck<br \/>Media:<br \/>Ron Rogers, 908-423-6449<br \/>or<br \/>Investors:<br \/>Carol        Ferguson, 908-423-4465     <\/p><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today that the U.S. District Court for the District of New Jersey has ruled in Merck&#8217;s favor in two jointly related patent infringement suits against Mylan Pharmaceuticals Inc. &#8220;The court appropriately ruled that the patent for ZETIA and VYTORIN in the U.S. is valid and enforceable,&#8221; said Bruce N. Kuhlik, executive vice president and general counsel of Merck. The patent at issue in this trial is RE 42,461 which covers ezetimibe, an active ingredient in both ZETIA and VYTORIN and expires April 2017. In its decision, the court upheld Merck&#8217;s patent on ZETIA and VYTORIN and ruled that the patent was valid and enforceable. Mylan had admitted that its product would infringe the patent. The court also issued an injunction blocking the approval of Mylan&#8217;s generic versions until the expiration of the patent. Mylan had been seeking U.S. Food and Drug Administration (FDA) approval to sell generic versions of ZETIA<\/p>\n","protected":false},"template":"","meta":{"_acf_changed":false,"bdl_company_name":[],"bdl_item_external_link":[],"inpsyde_pem_expiration_date":[],"inpsyde_pem_expiration_action":[],"footnotes":""},"tags":[53,289],"class_list":["post-742222","news_item","type-news_item","status-publish","hentry","tag-corporate-news","tag-press-release"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Merck Wins U.S. ZETIA\u00ae (ezetimibe)\/ VYTORIN\u00ae (ezetimibe\/simvastatin) Patent Infringement Lawsuit - Merck.com<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-wins-u-s-zetia-ezetimibe-vytorin-ezetimibe-simvastatin-patent-infringement-lawsuit\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Merck Wins U.S. ZETIA\u00ae (ezetimibe)\/ VYTORIN\u00ae (ezetimibe\/simvastatin) Patent Infringement Lawsuit - Merck.com\" \/>\n<meta property=\"og:description\" content=\"Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today that the U.S. District Court for the District of New Jersey has ruled in Merck&#039;s favor in two jointly related patent infringement suits against Mylan Pharmaceuticals Inc. &quot;The court appropriately ruled that the patent for ZETIA and VYTORIN in the U.S. is valid and enforceable,&quot; said Bruce N. Kuhlik, executive vice president and general counsel of Merck. The patent at issue in this trial is RE 42,461 which covers ezetimibe, an active ingredient in both ZETIA and VYTORIN and expires April 2017. In its decision, the court upheld Merck&#039;s patent on ZETIA and VYTORIN and ruled that the patent was valid and enforceable. Mylan had admitted that its product would infringe the patent. The court also issued an injunction blocking the approval of Mylan&#039;s generic versions until the expiration of the patent. Mylan had been seeking U.S. Food and Drug Administration (FDA) approval to sell generic versions of ZETIA\" \/>\n<meta property=\"og:url\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-wins-u-s-zetia-ezetimibe-vytorin-ezetimibe-simvastatin-patent-infringement-lawsuit\/\" \/>\n<meta property=\"og:site_name\" content=\"Merck.com\" \/>\n<meta property=\"article:modified_time\" content=\"2023-03-22T04:04:24+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-content\/uploads\/sites\/152\/2022\/03\/Merck.png\" \/>\n\t<meta property=\"og:image:width\" content=\"3056\" \/>\n\t<meta property=\"og:image:height\" content=\"1380\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-wins-u-s-zetia-ezetimibe-vytorin-ezetimibe-simvastatin-patent-infringement-lawsuit\\\/\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-wins-u-s-zetia-ezetimibe-vytorin-ezetimibe-simvastatin-patent-infringement-lawsuit\\\/\",\"name\":\"Merck Wins U.S. ZETIA\u00ae (ezetimibe)\\\/ VYTORIN\u00ae (ezetimibe\\\/simvastatin) Patent Infringement Lawsuit - Merck.com\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\"},\"datePublished\":\"2012-04-27T17:05:00+00:00\",\"dateModified\":\"2023-03-22T04:04:24+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-wins-u-s-zetia-ezetimibe-vytorin-ezetimibe-simvastatin-patent-infringement-lawsuit\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-wins-u-s-zetia-ezetimibe-vytorin-ezetimibe-simvastatin-patent-infringement-lawsuit\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-wins-u-s-zetia-ezetimibe-vytorin-ezetimibe-simvastatin-patent-infringement-lawsuit\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"News\",\"item\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news-archive\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Merck Wins U.S. ZETIA\u00ae (ezetimibe)\\\/ VYTORIN\u00ae (ezetimibe\\\/simvastatin) Patent Infringement Lawsuit\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/\",\"name\":\"Merck.com\",\"description\":\"Just another vip-msd.com site\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Merck Wins U.S. ZETIA\u00ae (ezetimibe)\/ VYTORIN\u00ae (ezetimibe\/simvastatin) Patent Infringement Lawsuit - Merck.com","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-wins-u-s-zetia-ezetimibe-vytorin-ezetimibe-simvastatin-patent-infringement-lawsuit\/","og_locale":"en_US","og_type":"article","og_title":"Merck Wins U.S. ZETIA\u00ae (ezetimibe)\/ VYTORIN\u00ae (ezetimibe\/simvastatin) Patent Infringement Lawsuit - Merck.com","og_description":"Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today that the U.S. District Court for the District of New Jersey has ruled in Merck's favor in two jointly related patent infringement suits against Mylan Pharmaceuticals Inc. \"The court appropriately ruled that the patent for ZETIA and VYTORIN in the U.S. is valid and enforceable,\" said Bruce N. Kuhlik, executive vice president and general counsel of Merck. The patent at issue in this trial is RE 42,461 which covers ezetimibe, an active ingredient in both ZETIA and VYTORIN and expires April 2017. In its decision, the court upheld Merck's patent on ZETIA and VYTORIN and ruled that the patent was valid and enforceable. Mylan had admitted that its product would infringe the patent. The court also issued an injunction blocking the approval of Mylan's generic versions until the expiration of the patent. Mylan had been seeking U.S. Food and Drug Administration (FDA) approval to sell generic versions of ZETIA","og_url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-wins-u-s-zetia-ezetimibe-vytorin-ezetimibe-simvastatin-patent-infringement-lawsuit\/","og_site_name":"Merck.com","article_modified_time":"2023-03-22T04:04:24+00:00","og_image":[{"width":3056,"height":1380,"url":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-content\/uploads\/sites\/152\/2022\/03\/Merck.png","type":"image\/png"}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-wins-u-s-zetia-ezetimibe-vytorin-ezetimibe-simvastatin-patent-infringement-lawsuit\/","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-wins-u-s-zetia-ezetimibe-vytorin-ezetimibe-simvastatin-patent-infringement-lawsuit\/","name":"Merck Wins U.S. ZETIA\u00ae (ezetimibe)\/ VYTORIN\u00ae (ezetimibe\/simvastatin) Patent Infringement Lawsuit - Merck.com","isPartOf":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website"},"datePublished":"2012-04-27T17:05:00+00:00","dateModified":"2023-03-22T04:04:24+00:00","breadcrumb":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-wins-u-s-zetia-ezetimibe-vytorin-ezetimibe-simvastatin-patent-infringement-lawsuit\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-wins-u-s-zetia-ezetimibe-vytorin-ezetimibe-simvastatin-patent-infringement-lawsuit\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-wins-u-s-zetia-ezetimibe-vytorin-ezetimibe-simvastatin-patent-infringement-lawsuit\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"News","item":"https:\/\/vip2-msd.com\/merckcom-migrated\/news-archive\/"},{"@type":"ListItem","position":2,"name":"Merck Wins U.S. ZETIA\u00ae (ezetimibe)\/ VYTORIN\u00ae (ezetimibe\/simvastatin) Patent Infringement Lawsuit"}]},{"@type":"WebSite","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/","name":"Merck.com","description":"Just another vip-msd.com site","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/vip2-msd.com\/merckcom-migrated\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"acf":{"news_item_workflow_id":"fdd8b73a-43cb-47dd-ae20-de8795844dd4","news_item_aria_label":"","media_files":null,"document_path":"","file":""},"_links":{"self":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/742222","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item"}],"about":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/types\/news_item"}],"version-history":[{"count":0,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/742222\/revisions"}],"wp:attachment":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/media?parent=742222"}],"wp:term":[{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/tags?post=742222"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}